Anti-Human GM-CSF

Purified Recombinant Human GM-CSF (>98%)

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: Measured by its ability to neutralize GM‑CSF-induced proliferation in the TF‑1 human erythroleukemic cell line. Kitamura, T. et al. (1989) J. Cell Physiol. 140:323. The Neutralization Dose (ND₅₀) is typically 0.08-0.16 µg/mL in the presence of 0.5 ng/mL Recombinant Human GM‑CSF.

Rabbit Anti-Human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) recognizes Human GM-CSF. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

Granulocyte-Macrophage Colony Stimulating Factor is a 22 kD, pleiotropic cytokine that is a white blood cell growth factor. It controls the production and function of blood cells by stimulating stem cells to produce granulocytes and monocytes. GM-CSF differs from G-CSF in that it affects more cell types including macrophages and eosinophils. Moreover, GM-CSF is part of the immune/inflammatory cascade, a process crucial for fighting infection. Interestingly, GM-CSF expression may have pathological implications. Autocrine expression of GM-CSF in myeloid leukemia cells is suspected to play a role in neoplasia, the formation of a new and abnormal growth of tissue. Additionally, GM-CSF expression has also been documented in certain solid tumors. There have also been reports of GM-CSF in synovial fluid from patients with arthritis suggesting that GM-CSF may play a role in tissue damage associated with the inflammatory process. Blocking GM-CSF is thought to have therapeutic potential by reducing inflammation. Some drugs are currently being developed to block GM-CSF.

1. Parker, MW. et al. (2008) Cell 134: 496 2. Whitsett, JA. et al. (2002) Annual Review of Physiology 64: 775